Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia

This activity is supported by an educational grant from Pharmacyclics, LLC, an AbbVie Company, and Janssen Biotech, Inc.

A continuing education article for nurse practitioners, clinical nurse specialists, advanced degree nurses, and oncology and hematology nurses.

Release date: July 18, 2017
Expiration date: November 13, 2017

Activity Rationale and Purpose
The therapeutic landscape of chronic lymphocytic leukemia (CLL) continues to change rapidly. Advances in pathology and genomics are also enabling researchers to use genetic tests to make more accurate risk assessments for various subgroups of CLL patients. Translating these advances into improved quality of care at the bedside poses a challenge; meeting this challenge will require continued education for advanced practitioners who are increasingly important members of the oncology care team.

Intended Audience
The activity’s target audience will consist of nurse practitioners, clinical nurse specialists, advanced degree nurses, and oncology and hematology nurses.
Learning Objectives

After completing this educational activity, participants should be able to:

1. Apply the principles of risk-adapted treatment using case-based scenarios to illustrate the impact of patient attributes and disease specific attributes
2. Manage toxicities associated with newer agents used to treat chronic lymphocytic leukemia
3. Describe the role of oral therapies in treating patients with chronic lymphocytic leukemia

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.

Nurses. This activity for 0.5 contact hour is provided by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 0.5 contact hour.

Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Meniscus Educational Institute has identified and resolved all conflicts of interest in accordance with the MEI policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

FACULTY

Sandra Kurtin, PhDc, ANP-C, AOCN®, has served as a consultant for AbbVie, Celgene, and Genentech.
Ali McBride, PharmD, BCOP, has served on the speakers bureau for AbbVie.

LEAD NURSE PLANNER
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

NURSE PLANNER
Wendy J. Smith, ACNP, AOCN®, has nothing to disclose.

PLANNERS
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Patti McLafferty has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

CONTENT REVIEWERS
Leslie Lauersdorf, ARNP, AOCNP, has served on the speakers bureau for Amgen.
Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit
To access the learning assessment and evaluation form online, visit http://meded.hbrsd.com/

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form with an E-mail address) will be able to download a statement of credit.
Selected Patient Cases From the APSHO Regional Lecture Series

Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia

SANDRA KURTIN, PhDc, ANP-C, AOCN®, and ALIC McBRIDE, PharmD, BCOP

INTRODUCTION

As the official publication of the Advanced Practitioner Society for Hematology and Oncology (APSHO), JADPRO is pleased to offer Part 3 of an accredited educational activity based on the recently concluded APSHO Regional Lecture Series. Hosted in collaboration with major cancer centers around the country, the APSHO Regional Lecture Series brought case-based didactic presentations and skills workshops to advanced practitioners.

In the spirit of JADPRO, three accredited Grand Rounds articles by Beth Eaby-Sandy, MSN, CRNP, OCN® (non-small cell lung cancer) and Sandra Kurtin, PhDc, ANP-C, AOCN® (multiple myeloma and chronic lymphocytic leukemia)—program chairs for the regional lecture series—offer the same practice-changing information and strategies for advanced practitioners.

In this Grand Rounds article, program chair Sandra Kurtin reviews the prognosis, risk assessment, and treatment for patients with chronic lymphocytic leukemia and assesses four case studies.

You can read Parts 1 and 2 in previous issues of JADPRO or online at advancedpractitioner.com. Check out apsho.org/lectures for information on registering for upcoming JADPRO Regional Lectures this year at a location near you.

J Adv Pract Oncol 2017;8:502-520
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the United States, with roughly 19,000 new cases diagnosed in 2016 (Siegel, Miller, & Jemal, 2017). The median age at diagnosis is 71 years, with nearly 70% of newly diagnosed patients over the age of 65 (Siegel et al., 2017; Stauder et al., 2016). Chronic lymphocytic leukemia is incurable in the absence of an allogeneic stem cell transplant. The disease trajectory is characterized by periods of stable disease, relapse, and in some cases Richter’s transformation. The 5-year relative survival rates have increased from 67.5% (1975–1977) to 81.7% (2005–2011); however, the clinical course of CLL is highly variable, ranging from indolent disease with a median survival exceeding 15 years without treatment, to more aggressive and relatively treatment-resistant disease with median survival of less than 4 years (Eichhorst & Hallek, 2016). This variability in life expectancy is in large part based on the molecular underpinnings of the disease, individual patient characteristics, and access to care.

There have been significant changes in the therapeutic landscape for CLL, due to enhanced understanding of the molecular features of CLL (Figure 1). In addition, several consensus statements and updated clinical guidelines have been developed. Personalized, tailored therapies based on risk assessment and risk-adapted treatment selection are now the standard of care. Chemioimmunotherapy and small-molecule agents have offered expanded options for treatment, including first-in-class agents. There have been nine US Food and Drug Administration (FDA) approvals for new drugs or expanded applications for existing compounds in less than 3 years. The research pipeline is robust, with additional approvals anticipated in the next 1 to 2 years. These advances offer hope to patients with CLL but require careful application of both diagnostic and prognostic strategies to achieve the improved clinical outcomes demonstrated in clinical trials.

The implications for oncology providers, including the advanced practitioner, are multifaceted. Lifelong learning, involvement in scientific discovery, vigilance in observing and reporting clinical experiences with novel agents in the postmarketing setting, familiarity with metrics for value-based care, and a commitment to improving patient outcomes will be necessary. The purpose of this article

Figure 1. Scientific and therapeutic innovation in chronic lymphocytic leukemia 2013–2017. R/R = relapsed/refractory; PR = partial response; CR = complete response. Information from Balducci & Dolan (2015); Parikh & Shanafelt (2016); Pflug et al. (2014); Rai & Jain (2016); Wierda (2015); Wierda et al. (2017).
is to provide the advanced practitioner in oncology with an update on risk assessment and risk-adapted treatment selection in patients with CLL using a case-based approach to demonstrate application of emerging data. The focus will be on the management of patients with currently approved agents, with mention of emerging therapies.

**PREDICTIVE AND PROGNOSTIC FEATURES OF CHRONIC LYMPHOCYTIC LEUKEMIA**

Chronic lymphocytic leukemia is characterized by mature B lymphocytes with an immunophenotype including CD5+, CD19+, CD20 weak, CD23+, and weak-surface expression of monoclonal immunoglobulin (Smlg-weak; Gruber & Wu, 2014). Small lymphocytic lymphoma (SLL) has the same immunophenotype as CLL but includes a predominance of nodal disease, bone marrow involvement, organomegaly, and < 5,000 tumor cells/μL. The clinical characteristics of the disease provided the basis for staging and prognosis for the past 50 years.

More recently, advances in flow cytometry, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) have elucidated features of the disease that confer either a favorable or unfavorable clinical course—and in some cases implications for treatment (Table 1). Features considered to confer an inferior survival advantage and in some cases refractory disease include the deletion of 17p or mutation of TP53, the presence of 11q or a complex karyotype (> 3 abnormalities in > 1 cell), < 2% (unmutated) immunoglobulin heavy-chain gene variable region (IgHV) mutation (uIgHV), > 30% CD38, and > 20% zeta-chain-associated protein 70 (ZAP-70; Parikh & Shanafelt, 2016).

Patients with uIgHV tend to have more aggressive disease, high expression of CD38, ZAP-70–positive disease, poor risk genetic profiles, and shorter survival (Montserrat et al., 2016). In a recent systematic review and meta-analysis including 31 studies, uIgHV was associated with inferior median progression-free survival (PFS; range, 1–5 years) and median overall survival (OS; range, 3.2–10 years) compared with patients with mutated IgHV (median PFS range, 9.2–18.9 years; median OS range, 17.9–25.8 years; Parikh, Strati, Tsang, West, & Shanafelt, 2016). In this same analysis, patients with del(17p13) and del(1q23), considered FISH high risk, had significantly shorter median PFS (range, 0.1–5.2 years) and median OS (range, 3.3–9.7 years) compared with patients with FISH low/intermediate-risk profiles including del(13q), normal, and trisomy 12 (median PFS range, 1.5–22 years; median OS range, 7.5–20.5 years; Parikh et al., 2016). Chronic lymphocytic leukemia with high expression of CD38 confers a less favorable prognosis due to the association of CD38 with migration and homing of CLL cells to secondary lymphoid organs. The malignant cells receive support from the tumor microenvironment in these lymphoid organs, causing suppression of immune surveillance through the production of tolerogenic compounds and increasing the risk of Richter’s transformation (Burgler, 2015; Parikh & Shanafelt, 2014). The tyrosine kinase ZAP-70, involved in cellular signaling of T cells, has been shown to correlate with the presence of uIgHV.

The heterogeneity of CLL is compounded by clonal evolution characterized by acquired genetic and epigenetic changes, which give rise to new subclones with emergence of one or more fitter or resistant subclones that become dominant (Guieze & Wu, 2015). Therefore, full characterization of the disease at the time of initial diagnosis and at disease progression is critical to effective risk analysis, prognostication, and clinical management of CLL. This includes reimaging; excisional biopsies in the case of rapidly progressive adenopathy; and a bone marrow biopsy with flow cytometry, FISH, and NGS when available to obtain a full molecular profile (Eichhorst & Hallek, 2016). Reevaluation of comorbidities and fitness for treatment is necessary for the optimal selection of treatment.

**RISK ASSESSMENT AND PROGNOSTICATION**

Given the heterogeneity of the disease, an international consortium of CLL experts convened to develop an internationally applicable prognostic index for CLL: the CLL-International Prognostic Index (CLL-IPI; 2016). Based on a retrospective analysis of 26 different items, 5 items were found to be independent predictors for OS (age, clinical
Table 1. Biomarkers and Clinical Attributes Used for Risk Assessment in Chronic Lymphocytic Leukemia

| Attribute | Clinical significance | Median OS (yr) |
|-----------|-----------------------|---------------|
| 17p13 deletion | • Present in 5%-20% of cases at the time of first-line treatment, 20%-40% in relapsed/refractory disease | 4 |
| | • Associated with TP53 mutation | |
| | • Unfavorable, inferior survival, resistance to chemoimmunotherapy | |
| | • Predisposed to aggressive tempo, Richter’s transformation, clonal evolution, and complex karyotype | |
| 1q22-23 deletion | • Present in 20%-25% of cases | 6 |
| | • Intermediate risk | |
| | • Associated with SF3B1, ATM, and BIRC mutations | |
| 13q14 deletion | • Present in 25%-40% of cases | 15 |
| | • Favorable risk when a sole abnormality, associated with MYD88 mutations | |
| Trisomy 12 | • Present in 15%-20% of cases | 7.5 |
| | • Intermediate risk | |
| | • Associated with NOTCH1 mutations, atypical immunophenotype | |
| | • Limited to no benefit from anti-CD20 antibodies | |
| Complex karyotype | • Unfavorable | - |
| | • Inferior survival | |
| | • Associated with del(17p)/TP53 mutation, advanced stage, CD38 expression, and elevated β2 microglobulin | |
| TP53 mutation | • Unfavorable | - |
| | • Inferior survival, resistance to chemoimmunotherapy | |
| | • Requires gene sequencing | |
| SF3B1 mutation | • Unfavorable | - |
| | • Correlates to Richter’s transformation | |
| | • Associated with del(11q) | |
| | • Inferior response to chemoimmunotherapy | |
| | • Requires gene sequencing | |
| NOTCH1 mutation | • Unfavorable | - |
| | • Correlates to Richter’s transformation | |
| | • Limited response to anti-CD20 antibodies | |
| | • Requires gene sequencing | |
| < 2% IgHV mutation (uIgHV) | • Present in 40% of cases | 3-6 |
| | • Unfavorable | |
| | • Correlated with TP53, NOTCH1, SF3B1, POT1 and XPO1 mutations, high expression of CD38, ZAP-70, and CD49d | |
| | • Correlated with aggressive tempo, shorter time to first treatment | |
| > 2% IgHV mutation (mIgHV) | • Present in 60% of cases | > 15 |
| | • Favorable | |
| | • Correlates with indolent disease, lack of unfavorable genetic features, longer time to first treatment | |
| | • Response to chemoimmunotherapy may translate to sustained MRD status, and OS like in normal healthy subjects | |
| > 30% CD38 | • CD38 confers a less favorable prognosis due to the association of CD38 with migration and homing of CLL cells to secondary lymphoid organs | - |
| > 20% ZAP-70 | • Unfavorable | - |
| | • Higher expression in uIgHV—used as a surrogate measure of uIgHV | |
| β2 microglobulin > 3.5 mg/L | • Unfavorable | - |
| | • Shorter time to initial treatment, lower complete remission rates, and shorter overall survival when receiving initial therapy with fludarabine-based regimens | |
| CIRS > 6 | • Correlates with age > 65, CrCl < 70 mL/min, ECOG ≥ 2, and β2 microglobulin > 3.5 mg/L | - |
| | • Fludarabine-based regimens do not add survival advantage when used as first-line treatment | |
| | • Score is based on the number of organ systems involved and the level of control for each comorbidity | |
| Age > 65 | • Correlates with increased CIRS | - |
| Rai stage | • Stage O (low risk): Lymphocytosis in blood and marrow only | 12.5 |
| | • Stage I and II (intermediate risk): Lymphadenopathy, splenomegaly ± hepatomegaly | 5.9-8.4 |
| | • Stage III and IV (high risk): Anemia (Hgb < 11.0 g/dL); thrombocytopenia (Plt < 100 x 109/L) + lymphadenopathy and splenomegaly | 1.5 |

Note. OS = overall survival; ZAP-70 = zeta-chain-associated protein 70; MRD = minimal residual disease; CLL = chronic lymphocytic leukemia; CrCl = creatinine clearance; ECOG = Eastern Cooperative Oncology Group; CIRS = Cumulative Illness Rating Score; Hgb = hemoglobin; Plt = platelets. Information from Eichhorst & Hallek (2016); Miller et al. (1992); Parikh & Shanafelt (2016); Rai et al. (1975); Roos-Well, Nguyen-Khac, & Bernard (2016); Rossi, Gerber, & Stussi (2017).
stage, 17p del and/or TP53 mutation, IgHV status, and \( \beta_{2} \) microglobulin). Each item was weighted according to regression analysis, with the presence of del(17p) or TP53 mutation carrying the highest weight (score of 4; hazard ratio [HR]: 4.2; \( p < .001 \)). When combined, these five factors produced four groups with significantly different OS rates (93%, 79%, 64%, and 23% at 5 years; \( p < .001 \); the International CLL-IPI Working Group, 2016; Table 2).

Given the older age of most patients with CLL, consideration of fitness and frailty as well as the presence of comorbidities is crucial when considering treatment (Goede et al., 2014; Stauder et al., 2016). The presence of comorbidities, particularly when poorly controlled, is associated with an increased risk of treatment-related adverse events, inferior survival, decreased access to care, and inferior quality of life (Sarfati et al., 2016).

RISK-ADAPTED TREATMENT SELECTION

The goals of therapy in CLL include early identification of high-risk disease, estimation of the time to treatment, early identification of lack of or loss of response to treatment, prevention of infections, preservation of future treatment options by limiting end-organ damage and cumulative treatment toxicity, and ultimately maintenance or improvement in quality of life. Applying the findings from the risk assessment will help to avoid overtreatment and unnecessary exposure to adverse events as well as undertreatment and suboptimal therapeutic benefit. Risk-adapted treatment, including consideration of disease attributes, line of therapy, and patient attributes, is essential to maximizing outcomes and quality of life (Figure 2). All patients should receive palliative and supportive care, which should be tailored to the individual patient and regimen and initiated at the time of diagnosis. Potential disease and treatment-emergent adverse events must be considered in the context of individual patient attributes when considering the risks associated with treatment (Table 3).

TREATMENT OF NEWLY DIAGNOSED CHRONIC LYMPHOCYTIC LEUKEMIA

It is tempting to initiate treatment early in patients with CLL, given the number of newly developed agents with unique mechanisms of action and promising outcomes. However, there are no data to date to change the recommendations for treatment set forth by the International CLL-IPI Working Group (Table 2).

---

**Table 2. The Chronic Lymphocytic Leukemia International Prognostic Index (Training Cohort, \( n = 1,214 \))**

| Prognostic factor | Adverse factor | Regression coefficient | Hazard ratio (95% CI) | \( p \) value | Weighted score |
|-------------------|----------------|------------------------|-----------------------|---------------|---------------|
| CLL FISH panel    | 17p deletion/TP53 mutation | 1.434 | 4.2 (3.2–5.5) | < .0001 | 4 |
| IgHV              | Unmutated    | 0.950 | 2.6 (2.1–3.2) | < .0001 | 2 |
| \( \beta_{2} \) microglobulin concentration | > 3.5 mg/L | 0.678 | 2.0 (1.6–2.4) | < .0001 | 2 |
| Clinical stage    | Rai I–IV or Binet B–C | 0.464 | 1.6 (1.3–1.9) | < .0001 | 1 |
| Age               | > 65 years   | 0.555 | 1.7 (1.4–2.1) | < .0001 | 1 |

**Risk category**

- **Low**
  - Composite risk score: 0–1
  - Patients (\( n = 1,214 \)): 341 (28%)
  - Median OS months (95% CI): NR
  - 5-year OS (95% CI): 93.2% (90.5–96.0)
  - 10-year OS (95% CI): 79.0% (71.8–86.3)

- **Intermediate**
  - Composite risk score: 2–3
  - Patients (\( n = 1,214 \)): 474 (39%)
  - Median OS months (95% CI): 105 (96–119)
  - 5-year OS (95% CI): 79.3% (75.5–83.2)
  - 10-year OS (95% CI): 39.2% (31.0–47.4)

- **High**
  - Composite risk score: 4–6
  - Patients (\( n = 1,214 \)): 337 (28%)
  - Median OS months (95% CI): 75 (68–82)
  - 5-year OS (95% CI): 63.3% (57.9–68.8)
  - 10-year OS (95% CI): 21.9% (14.2–29.6)

- **Very high**
  - Composite risk score: 7–10
  - Patients (\( n = 1,214 \)): 62 (5%)
  - Median OS months (95% CI): 29 (18–40)
  - 5-year OS (95% CI): 23.3% (12.5–34.1)
  - 10-year OS (95% CI): 3.5%* (NE)

**Note.** CLL = chronic lymphocytic leukemia; FISH = fluorescence in situ hybridization; NR = not reached; NE = not evaluable; OS = overall survival. Information from International CLL-IPI Working Group (2016).

*At the time of the last observation (month 93).
Let’s apply the metrics of risk assessment to three patients with previously untreated CLL.

**Case Study 1**
Mrs. J is a 75-year-old female who presented to her primary care physician (PCP) 2 weeks ago with palpitations, progressive fatigue, and increased joint pain. She was noted to have an elevated white blood cell (WBC) count (96 × 1,000/μL), moderate anemia (hemoglobin [Hgb] 8.1 g/dL), and thrombocytopenia (97 × 1,000/μL). Flow cytometry on the peripheral blood confirms a diagnosis of CLL. A bone marrow biopsy is performed showing 90% involvement of the bone marrow by CLL, normal female karyotype, ZAP-70–negative, β₂ microglobulin 3.4 m/L, and mutated IgHV. A noncontrast computed tomography (CT) shows no significant adenopathy and no splenomegaly. She has a history of atrial fibrillation, chronic renal insufficiency (creatinine clearance [CrCl] 55 mL/min), and osteoarthritis. She is married and lives with her husband, who is relatively healthy. They walk with their dog daily.

**Risk Assessment:**
- Rai stage: III
- Cumulative Illness Rating Scale (CIRS) = 3
- CLL-IPI score: 2 (age > 65, Rai stage III) = intermediate risk
- The International CLL-IPI Working Group

![Diagram](image-url)
criteria for treatment: Yes—progressive fatigue, cytopenias, fevers without infection
- Risk-adapted treatment selection: either a clinical trial or the combination of bendamustine plus rituximab

Case Study 2
Mrs. R is a 72-year-old female who presented with recurring pharyngitis, low-grade fevers, progressive fatigue, adenopathy, abdominal pain, and > 10% weight loss. Her medical history includes hypertension, gastroesophageal reflux disease, hypothyroidism, cholelithiasis, shingles, exaggerated reaction to insect bites, and chronic pain due to a previous car accident. She was diagnosed with CLL 1 year ago based on peripheral blood analysis and has been monitored off treatment.

On a physical exam, she has extensive adenopathy in the cervical, axillary, and inguinal regions as well as palpable splenomegaly. Other diagnostic findings include: WBC count: 230.7 × 1,000/μL; absolute lymphocyte count (ALC): 223.78 × 1,000/μL; Hgb: 10.9 g/dL; platelets: 180 × 1,000/μL; lactate dehydrogenase (LDH): 250 IU/L (upper limit of normal [ULN] 243), β2 microglobulin: 2.5 mg/L, ZAP-70–positive. A bone marrow biopsy is performed, showing 80% involvement with small mature noncleaved lymphocytes, metaphase cytogenetics with a normal female karyotype (46, XX[15]), and FISH with 17p13 deletion in 92/200 cells.

Risk Assessment:
- Rai stage: III (Hgb < 11 g/dL, splenomegaly, adenopathy, lymphocytosis)
- CIRS: 5
- CLL-IPI score: 8 (17p+, Rai stage I–IV, IgHV unmutated, age > 65) = very high risk
- The International CLL-IPI Working Group criteria for treatment: Yes—progressive fatigue, cytopenias, fevers without infection
- Risk-adapted treatment selection: either a clinical trial or ibrutinib (Imbruvica)

Case Study 3
Mr. B. is a 75-year-old male diagnosed as Binet stage 0 CLL. His disease profile includes small to medium adenopathy (0.7 cm–2.7 cm), FISH with trisomy 11q, mutated IgHV (mIgHV). His medical history includes psoriasis, seasonal sinus infections, and benign prostatic hyperplasia (BPH). He is here for a scheduled follow-up visit. Labs: WBC (25.5 × 1,000/μL); ALC 18.62 × 1,000/μL; normal β2 microglobulin, and no cytopenias. He does report fatigue, but this has not changed. He is recently widowed and is depressed.

Risk Assessment:
- Rai stage: 0 (asymptomatic)
- CIRS: 1
- CLL-IPI score: 1 (age > 65) = low risk
- The International CLL-IPI Working Group criteria for treatment: No—he has no indications to treat
- Risk-adapted treatment selection: surveillance/watch and wait

Discussion
These case studies illustrate the significance of a comprehensive risk assessment to determine the need for treatment and the selection of therapy. The patient in case study 3 does not meet the International CLL-IPI Working Group criteria for treat-
ment. Although he has the del(11q), a higher-risk feature, this alone does not indicate the need for treatment (International CLL-IPI Working Group, 2016). The patients in case study 1 and 2 meet the International CLL-IPI Working Group criteria to initiate treatment; however, the preferred regimen for treatment in each case is very different.

In case study 1, the patient has mIgHV, with intermediate-risk disease. Patients with mIgHV in the absence of any other adverse risk factors

| Common Adverse Events Associated With FDA-Approved Oral Agents for Chronic Lymphocytic Leukemia Based on Prescribing Information |
|---------------------------------------------------------------|
| **Adverse event (%) (Alphabetical order)** | **Ibrutinib** | **Idelalisib** | **Venetoclax** |
| | **All grades** | **Grade ≥ 3** | **All grades** | **Grade ≥ 3** | **All grades** | **Grade ≥ 3** |
| ALT/AST elevation | NR | NR | 28–39 | 11-18 # | NR | NR |
| Anemia | 33–46 | 0 | NR | NR | 29 | 18 |
| Anorexia | 21 | 2 | 16 | 2 | NR | NR |
| Arthralgia/myalgia | 16-59 | 0–2 | NR | NR | 10 | < 1 |
| Atrial fibrillation | 6-16 | 2–6 # | NR | NR | NR | NR |
| Bleeding/hemorrhage | 44–69 | 0–6 # | NR | NR | NR | NR |
| Bruising | 20–26 | 0–2 | NR | NR | NR | NR |
| Colitis | NR | NR | – | 14–19 ! | NR | NR |
| Contraindications | None | History of serious allergic reactions | | Concomitant use of strong inhibitors of CYP3A at initiation and during ramp-up |
| CYP3A interactions | Yes | Yes | Yes |
| Diarrhea | 36–59 | 4 | 32 | 11 # | 35 | < 1 |
| Dose modification | Hepatic/hematologic | Hepatic/hematologic | Hepatic/hematologic/TLS |
| Edema | 8–29 | 0–1 | NR | NR | 11 | < 1 |
| Embryofetal toxicity | Possible # | Possible # | Possible # |
| Fatigue/lethargy | 5–30 | 0–5 | 5 | 0 | 21 | 2 |
| Hypertension | 11–16 | 4–8 # | NR | NR | NR | NR |
| Infections | See pneumonia/URI | 5–9 | 21–36 ! | See pneumonia/URI |
| Intestinal perforation | NR | NR | Reported | NR | NR |
| Lymphopenia | NR | NR | 21 | 10 | NR | NR |
| Nausea | 16–20 | 0–2 | 30 | 1 | 33 | < 1 |
| Neutropenia | 4–24 | 0–5 # | 65 | 42 | 45 | 41 # |
| Pneumonia/URI | 10–26 | 4–20 # | 30 | 21 | 30 | 6 |
| Pneumonitis | NR | NR | – | 4 ! | NR | NR |
| Rash | 3–47 | 0–3 | 27 | 4 | NR | NR |
| Sepsis | NR | NR | NA | 9 | NR | NR |
| SPM | 3–16 | NA | NR | NR | NR | NR |
| Laboratory TLS’ | Rare; # | 0 | NR | NR | 6 | 6 # |
| Thrombocytopenia | 16–21 | 5–10 # | NR | NR | 22 | 15 |

Note. FDA = US Food and Drug Administration; ALT = alanine aminotransferase; AST = aspartate aminotransferase; NR = not reported; # = warning and precautions; ! = black box warning; URI = upper respiratory infection; SPM = secondary primary malignancies; TLS = tumor-lysis syndrome; + = using ramp-up dosing of venetoclax. Information from AbbVie (2016); Gilead (2017); Pharmacyclics (2016).
may enjoy a longer time to treatment initiation. In addition, once treated with fludarabine, cyclophosphamide, and rituximab (FCR), these patients may experience long-term remissions and may in fact be potentially cured of their disease (Fischer et al., 2016; Thompson et al., 2016). This patient is older and does have comorbidities, which would increase the risk associated with FCR. Patients who are not candidates for this more intensive chemoimmunotherapy may benefit from bendamustine and rituximab (BR).

In the phase III CLL 10 trial comparing frontline BR and FCR in 561 patients with a CIRS < 6 and CrCl > 70 mL/min, without del(17p), median PFS was 41.7 months (95% confidence interval [CI] = 34.9–45.3) with bendamustine and rituximab and 55.2 months (95% CI not evaluable) with FCR (HR, 1.643; 90.4%; CI = 1.308–2.064) at 37 months of follow-up (Eichhorst et al., 2016). Objective response rate (ORR) was equivalent in each treatment group (95.4% vs. 95.7%; p = 1.0); however, patients in the FCR group were significantly more likely than those treated with BR to achieve a complete response (39.7% vs. 30.8%; p = .034). No differences in OS between the FCR and BR groups were noted at 36 months of follow-up (90.6% vs. 92.2%; p = .897). Adverse events, including severe neutropenia and infections, were more frequently observed with FCR when compared with BR, and serious infections were more common in patients over the age of 65 receiving FCR (Eichhorst et al., 2016). Therefore, FCR is not recommended for older or frail patients.

The patient in case study 2 has very high-risk disease, with a CLL-IPI score of 8. The presence of del(17p) accounts for 4 points alone. Standard chemoimmunotherapy is not effective in patients with del(17p). There are only two agents approved for treatment specifically in the presence of del(17p), including ibrutinib and venetoclax (Venclexta). Alem-tuzumab has established activity in this setting but is no longer commercially available for treatment of CLL; however, it can be obtained for clinical use. It is not effective in patients with bulky disease and is associated with a higher risk of reactivation of cytomegaloviral infections (Wierda et al., 2017).

**Ibrutinib**

Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, has a broad indication in the treatment of CLL in treatment-naïve (TN), relapsed or refractory (RR), and del(17p) CLL patients as well as those over the age of 65 (Foluso, Glick, Stender, & Jaiyesimi, 2016; Maddocks & Jones, 2016). It was first approved in February of 2014 as a single agent for treatment of patients with CLL after one prior therapy (Byrd et al., 2013, 2014). Continued clinical trials using ibrutinib as a single agent and in combination with BR led to its expanded approval for use in the front-line setting, including for older patients (Burger et al., 2015; O’Brien et al., 2014), and in combination with BR in patients with RR CLL (Chanan-Khan et al., 2016).

Among the 656 CLL patients participating in these trials, the ORR ranged from 63% to 88% in RR CLL and 97% in TN CLL, including patients with del(17p), 11q, and uIgHV (Farooqui et al., 2015; Foluso et al., 2016; Jain et al., 2017). Although response rates and PFS outcomes in these trials are promising, complete responses were rare, indicating a need to explore other novel combinations (Jain et al., 2017). Several trials are underway evaluating these novel combinations as well as second-generation BTK inhibitors (Table 5).

Recent publications evaluating long-term outcomes for CLL patients treated with ibrutinib in both TN CLL and RR CLL have elucidated several important points: (1) Uncontrolled adverse events continue to be a leading cause of treatment discontinuation—the most common adverse events cited for early discontinuation of ibrutinib included atrial fibrillation, infection, pneumonitis, bleeding, and diarrhea (Barr et al., 2016; Byrd et al., 2017; Jain et al., 2017; Mato, 2016); (2) Adverse-event profiles in the postmarketing setting are mostly consistent with profiles reported in the clinical trials, with some variations in frequency and severity in patients on long-term treatment including persistent hypertension and the incidence of atrial fibrillation and bleeding episodes (Barr et al., 2016; Gashonia et al., 2017; Kunk et al., 2016; Mato et al., 2016; Shanafelt et al., 2017; Yun, Vincelette, Acharya, & Abraham, 2017); (3) Patients who discontinued ibrutinib due to progression of disease may benefit from other small-molecule agents; however, those who progress with Richter’s transformation have an extremely poor prognosis, with an estimated life expectancy of 1.5 years (Mato et al., 2016).
Pretreatment risk assessment is critical to mitigating risks and should include collaboration with co-managing providers such as PCPs and cardiologists to reduce potential drug-drug interactions and optimally manage expected adverse events. Factors shown to correlate with an increased risk of treatment-emergent atrial fibrillation include older age (≥ 75 years), male sex, valvular heart disease, and hypertension (Shanafelt et al., 2017; Yun et al., 2017). Anticoagulation, a proven method for reducing the potential for ischemic stroke in the setting of atrial fibrillation, can be safely managed in CLL patients receiving ibrutinib but requires vigilance and engagement of the patient in early reporting of adverse events and maintaining safety (Yun et al., 2017). Infections, particularly sinopulmonary infections, are common in the general CLL population. Atypical infections are also more common in CLL, owing to chronic immunosuppression associated with the disease and treatment. Vigilance in monitoring and methods to prevent atypical infections is recommended.

**Oral Adherence**

Based on the mechanism of action, the current recommendation for all small molecules, including ibrutinib, is to continue treatment until disease progression or unacceptable toxicity. Although scientifically sound, this principle presents many potential barriers to younger patients with a life expectancy of more than a couple of years, including adherence and unknown long-term toxicities (Barrientos, 2016). Oral ad-

---

**Table 5. Selected Clinical Trials Currently Recruiting Using Novel Agents for the Treatment of Chronic Lymphocytic Leukemia**

| Trial ID | NCT #       | Regimen                                                                 | CLL population                                      | Phase |
|----------|-------------|-------------------------------------------------------------------------|----------------------------------------------------|-------|
| CLL12    | NCT02863718 | Ibrutinib vs. watch and wait                                            | TN Binet stage A                                   | III   |
| E1912    | NCT02048813 | FCR + ibrutinib vs. ibrutinib + rituximab                             | Young, fit, TN                                     | –     |
| AO41202  | NCT01886872 | BR vs. ibrutinib + rituximab                                           | 65 years or older, TN                              | –     |
| 150172   | NCT02514083 | Ibrutinib + short-course fludarabine                                    | Fit, TN                                            | II    |
| CLL2-GiVe| NCT02758665 | Ibrutinib + venetoclax + obinutuzumab                                  | Fit, TN, with TP53 deletion (17p-) and/or mutation | II    |
| CLL13    | NCT02950051 | FCR/BR vs. rituximab + venetoclax vs. obinutuzumab + venetoclax         | Fit, TN, no del(17p) nor TP53 mutation             | III   |
| CLL2-BIO | NCT02689141 | Bendamustine followed by ofatumumab and ibrutinib followed by ofatumumab maintenance | All-comer population with indication for treatment | II    |
| CLL2-BCG | NCT02445131 | Bendamustine followed by obinutuzumab + idealtisib followed by idealtisib maintenance | All-comer population with indication for treatment | II    |
| UTX-TGR-304 | NCT02612311 | Ublituximab + TGR-1202 vs. obinutuzumab + chlorambucil                 | TN or RR, no prior obinutuzumab, PI3K, or chlorambucil | III   |
| CLLR3    | NCT02320383 | Fludarabine + cyclophosphamide + obinutuzumab vs. bendamustine + obinutuzumab | Fit, RR, no more than 3 prior regimens for CLL     | II    |
| MDA 20150860 | NCT02756897 | Venetoclax + ibrutinib                                                 | TN with high-risk features RR                       | II    |
| 141106   | NCT02315768 | Ibrutinib + obinutuzumab                                               | All-comer population with indication for treatment | I/II  |
| ACE-CL-208 | NCT02717611 | ACP-196 (acalabrutinib)                                                | RR                                                 | II    |

Note. TN = treatment naive; FCR = fludarabine, cyclophosphamide, and rituximab; BR = bendamustine and rituximab; RR = relapsed refractory; PI3K = phosphoinositide 3-kinase. Information from clinicaltrials.gov.
herence is a continuous challenge across cancer diagnoses. Patients missing ≥ 8 consecutive days of ibrutinib had a shorter median PFS than did those missing < 8 days (10.9 months vs. not reached; Barr et al., 2017).

Drug-drug interactions are common with small-molecule agents used to treat CLL and may either increase the risk of treatment-emergent adverse events, reduce the efficacy of novel agents, or modify the safety and efficacy of concomitant medications (Finnes et al., 2016).

A recent study evaluating perceptions of adherence communication and actual adherence in patients with CLL (81 physicians and 326 patients) showed a disparity between what physicians reported (87% indicated their CLL patients were “always” or “almost always” adherent) and patients reported (42% of patients reported they were “never” or “hardly ever” nonadherent to CLL treatment; Schnekel, Hallworth, Rider, Maccomson, & McRae, 2017).

The advanced practitioner in oncology plays a pivotal role in communication with the patient and among the interprofessional team. Establishing a program and process for support of patients on oral antineoplastic agents, including evaluation and management of possible drug-drug or drug-food interactions, is essential to safety and continued treatment with novel agents.

Monoclonal Antibodies

Monoclonal antibodies, including obinutuzumab (Gazyva), ofatumumab (Arzerra), and rituximab, provide a cadre of well-tolerated options for treatment of CLL in the front-line or RR setting (Chaoui et al., 2017; Wierda et al., 2017; Figure 2). They have become a mainstay in the treatment of lymphoid malignancies. Although they have limited benefit as single agents, when combined with standard chemotherapy (bendamustine, chlorambucil, fludarabine, cyclophosphamide), they provide safe and effective options for treatment with well-known and acceptable adverse events (Table 6). More recently, monoclonal antibodies are being combined with novel agents, with early data suggesting these “no chemotherapy required” regimens as feasible options for the treatment of CLL in the front-line, RR, and maintenance settings (Wierda et al., 2017; Table 5).

TREATMENT OF RELAPSED OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Treatment of RRCLL requires re-evaluation of both patient- and disease-related factors. Analysis of prior therapies, response and tolerance of the prior therapies, any new or unresolved adverse events, and the presence of any acquired adverse disease features is essential. Let’s consider a patient with RRCLL.

Case Study 4

Mr. C is a 47-year-old male with a 10-year history of Rai stage I CLL with del(13q), ZAP-70–negative, normal β₂-microglobulin, and mutated IgHV at the time of diagnosis. He was previously treated with six cycles of FCR, achieving a complete response. It has been 7 years since his treatment. He presents to clinic with a new cervical lymph node, increased fatigue, abdominal pain, intermittent diarrhea, and shortness of breath when he bends over. His WBC count is 47 × 1,000/μL with lymphocytosis, mild anemia (Hgb 11.2 g/dL), and a platelet count slightly below normal (137 × 1,000/μL).

On physical exam, you note an enlarged spleen. Computed tomography scan of the chest, abdomen, and pelvis shows moderate splenomegaly and scattered adenopathy, with the abdomen with the largest nodal conglomerate in the mesentery (measuring 5.8 cm in greatest dimension). The FISH analysis shows the presence of del(17p). He has no other medical or surgical history. He is married, working full time, and has two children. He denies night sweats or unexplained weight loss.

Risk Assessment:

- CIRS: 0
- CLL-IPI score: 5
- The International CLL-IPI Working Group criteria for treatment: Yes
- Risk-adapted treatment selection: clinical trial, ibrutinib or venetoclax followed by allogeneic stem cell transplant

In patients who relapse more than 3 years after treatment with FCR or BR, repeating those regimens may be reasonable unless they have acquired del(17p) (Barrientos, 2016). The patient in case study 4 was treated more than 3 years ago with FCR and enjoyed a time-to-treatment interval of 7 years. However, he has an
acquired del(17p), which changes his risk profile and the recommendation for treatment. Clonal evolution, the acquisition of new cytogenetic abnormalities during the disease course, is thought to drive CLL relapse and has implications for OS (Roberts & Huang, 2017; Woyach et al., 2014). The acquisition of high-risk abnormalities, particularly del(17p), is associated with inferior OS, whereas the acquisition of low- or intermediate-risk abnormalities (trisomy 12, deletion 13q) does not independently change the estimated OS. Therefore, all patients should be re-evaluated for acquired adverse-risk features and their level of fitness at the time of relapse or disease progression to effectively guide treatment decisions.

For this patient, a clinical trial with the end-point being allogeneic stem cell transplant would be ideal. Alternatively, a regimen that incorporates agents with proven efficacy in patients with del(17p) CLL, either ibrutinib or venetoclax, as a bridge to transplant is optimal. Ibrutinib has been previously discussed in detail. Older or less fit patients, or those without del(17p), may be considered for alternative regimens (Figure 2).

Table 6. Common Adverse Events Associated With FDA-Approved Monoclonal Antibodies for Chronic Lymphocytic Leukemia

| Adverse event (%) (Alphabetical) | Obinutuzumab | Ofatumumab | Rituximab |
|----------------------------------|-------------|------------|-----------|
|                                  | All grades | Grade ≥ 3 | All grades | Grade ≥ 3 | All grades | Grade ≥ 3 |
| ALT/AST elevation                | 28         | 2          | NR         | NR         | NR         | NR         |
| Anemia                           | 39         | 10         | NR         | NR         | 8          | 3          |
| Arthralgia/myalgia               | 12         | 0          | 5          | < 1        | 10         | 1          |
| Contraindications                | None       | None       | –          |            |            |            |
| Cough                            | 26         | 0          | NR         | NR         | 13         | 1          |
| Diarrhea                         | 10         | 2          | NR         | NR         | 10         | 1          |
| Edema                            | NR         | NR         | NR         | NR         | 11         | 1          |
| Embryofetal toxicity             | Possible   | Possible   | Possible   |            |            |            |
| Fatigue/lethargy                 | 11         | 1          | 8          | < 1        | 26         | 1          |
| Hepatitis B reactivation         | Possible ! | Possible ! | Possible ! |            |            |            |
| Hypoalbuminemia                  | 23         | < 1        | 5          | < 1        | –          |            |
| Immunizations                    | Do not administer live virus vaccines | Do not administer live virus vaccines | Do not administer live virus vaccines |
| Infusion reactions               | 66         | 20 #       | 67         | 10 #       | 77         | 10 #       |
| Lymphopenia                      | 84         | 35         | 52         | 29         | 48         | 40         |
| Mucocutaneous reactions/bowel perforation or obstruction | NR | NR | NR | NR | Reported !|
| Nausea                           | NR         | NR         | NR         | NR         | 23         | 1          |
| Neutropenia                      | 76         | 46 #       | 27         | 26 #       | 14         | 6          |
| PML                              | Possible ! | Possible ! | Possible ! |            |            |            |
| TLS                              | Possible # | NR         | NR         | NR         |            |            |
| Thrombocytopenia                 | 48         | 13 #       | NR         | NR         | 12         | 2          |
| URI/pneumonia/sinus              | 15         | 3          | 36         | 6          | 31         | 4          |

Note. FDA = US Food and Drug Administration; ALT = alanine aminotransferase; AST = aspartate aminotransferase; # = warning and precautions; ! = black box warning; NR = not reported; URI = upper respiratory infection; PML = posterior multifocal leukoencephalopathy; TLS = tumor-lysis syndrome. Information from Genentech (2016); Genentech (2017); Novartis (2017).
Idelalisib (Zydelig), a first-in-class, oral, selective, phosphoinositide 3-kinase (PI3K) δ inhibitor, was approved for the treatment of relapsed SLL in patients who have received at least two prior systemic therapies and for the treatment of relapsed CLL in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy because of other comorbidities (Gilead, 2016). Approval of idelalisib was based on a phase III randomized trial in a primarily older patient population (78% age > 65) with comorbidities (85% with CIRS > 6). Idelalisib offers a good option for selected patients in the second-line setting but must be balanced with a toxicity profile that includes a black box warning for fatal and severe hepatotoxicity, diarrhea or colitis, pneumonitis, and intestinal perforation (Gilead, 2016; Table 4). Ongoing trials are evaluating idelalisib in combination with monoclonal antibodies with and without novel agents (Table 5). Given the goal of transition to stem cell transplant and the risk of infections and gastrointestinal toxicity, this would not be the first choice of treatment in this young patient.

Venetoclax, a first-in-class small-molecule inhibitor of BCL2, is approved for the treatment of patients with CLL with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy (AbbVie, 2016). Approval of venetoclax was based on data from phase I and II trials, with 79% of all patients in both trials achieving an objective response, regardless of the dose of venetoclax (Roberts & Huang, 2017). In addition, 20% of patients in these trials achieved a complete response, including patients with a del(17p) deletion. Although minimal residual disease (MRD) status was not included in the initial evaluation, a subset of patients achieved MRD-negative status.

Like other small-molecule agents, venetoclax has adverse events that require risk assessment and measures for prevention (Table 4). Tumor lysis syndrome (TLS) is included in the warnings and precautions. Two fatal events and three cases of acute renal failure, with one requiring dialysis, were reported in the initial phase I trial. Subsequent modification of the dosing using a ramp-up method, together with guidelines for evaluation of TLS risk, prevention, and management, resulted in only 6% of patients on the phase II trial reported as having laboratory TLS. No cases of clinical TLS were noted (Roberts et al., 2016). The time to response with venetoclax is rapid, ranging from 0.1 to 8.1 months. Therefore, careful assessment of the risk of TLS prior to initiating therapy is required for safety. Patients at higher risk require inpatient administration of venetoclax and more intensive prevention and monitoring with the initial ramp-up. These guidelines can be found in the prescribing information for venetoclax and are also included in the National Comprehensive Cancer Network® Guidelines. As with other novel agents used in the treatment of CLL, venetoclax is being combined with other agents in ongoing clinical trials.

**CONCLUSIONS**

Chronic lymphocytic leukemia is a heterogeneous disease with variability in prognosis, disease trajectory, and survival. This is primarily a disease of older adults. The robust pace of scientific development has improved our understanding of the underlying pathobiology of the disease and has elucidated actionable targets to produce novel therapies, ultimately expanding treatment options and in many cases improving therapeutic outcomes. None of these agents would be available in the absence of clinical trials. Therefore, every patient should be considered for a clinical trial regardless of the stage of disease or the line of therapy.

Treatment after failure of novel agents presents a challenge. Emerging trials using novel agents in rational combinations based on their mechanism of action, signaling pathways, and targets offer hope in generating therapies that more effectively exploit the vulnerabilities in CLL cells and their microenvironment. This will require lifelong learning on the part of all oncology professionals.

Safe and effective integration of these new therapies presents a challenge for the advanced practitioner in oncology. Risk assessment and prognostication followed by risk-adapted treatment selection will promote selection of the best available therapy and limit overtreatment of patients who are unfit. The ability to anticipate, prevent, and identify adverse events, and then intervene promptly to mitigate risk, is critical to maximizing outcomes. Understanding the unique toxicity profiles of novel
therapies and integrating this into risk-adapted treatment selection is critical to mitigating this risk.

### SPECIAL NOTE: PRIMING THE PUMP

Condensing the plethora of scientific advances and implications for clinical practice into one article is impossible, and not all agents, regimens, or clinical trials have been reviewed. The Advanced Practitioner Society for Hematology and Oncology (APSHO) has embarked on a new educational and practice initiative entitled “Priming the Pump” (PTP). The PTP initiative is aimed at creating and maintaining an intuitive and interactive foundation of knowledge relative to emerging therapies. This initiative will include several comprehensive supplements to JADPRO, each focusing on a different disease state, covering discussion of the disease, relevant therapeutic pathways, targets, and treatment options, with the role of the advanced practitioner always at the core.

The PTP supplement on CLL, to be published at the end of this year, will provide a comprehensive review of the pathobiology of CLL, diagnostic evaluation, risk-adapted treatment selection, management of adverse events, and discussion of ongoing clinical trials and emerging agents.

### Disclosure

Ms. Kurtin has served as a consultant for AbbVie, Celgene, and Genentech. Dr. McBride has served on the speakers bureau for AbbVie.

### References

AbbVie. (2016). Venclexta (venetoclax) package insert. Retrieved from http://www.rxabbvie.com/pdf/venclexta.pdf

Balducci, L., & Dolan, D. (2015). Chronic lymphocytic leukemia in the elderly: Epidemiology and proposed patient-related approach. *Cancer Control, 22*(4 Suppl), 3–6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26618340

Barr, P. M., Brown, J. R., Hillmen, P., O’Brien, S., Barrientos, J. C., Reddy, N. M.,...Byrd, J. C. (2017). Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. *Blood, 129*(19), 2612–2615. https://doi.org/10.1182/blood-2016-12-737346

Barr, P. M., Robak, T., Owen, C. J., Tedeschi, A., Bairey, O., Bartlett, N. L.,...Ghia, P. (2016). Updated efficacy and safety from the phase 3 Resonate-2 study: Ibrutinib as first line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic lymphoma [Abstract 234]. *Blood (ASH Annual Meeting Abstracts), 128.*

Barrientos, J. C. (2016). Sequencing of chronic lymphocytic leukemia therapies. *Hematology American Society of Hematology Education Program, 2016*(1), 128–136. https://doi.org/10.1182/ashducation-2016.1.128

Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P.,...Kipps, T. J. (2015). Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *New England Journal of Medicine, 373*(25), 2425–2437. https://doi.org/10.1056/NEJMoa1509388

Burgler, S. (2015). Role of CD38 expression in diagnosis and pathogenesis of chronic lymphocytic leukemia and its potential as therapeutic target. *Critical Reviews in Immunology, 35*(5), 417–432. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26853852

Byrd, J., Hillmen, P., O’Brien, S. M., Barrientos, J. C., Reddy, N. M., Coutre, S.,...Brown, J. R. (2017). Long-term efficacy and safety with ibrutinib in previously treated chronic lymphocytic leukemia: Up to four years of follow-up of the RESONATE study [Abstract 7510]. *Journal of Clinical Oncology (Meeting Abstracts), 35*(suppl).

Byrd, J. C., Brown, J. R., O’Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M.,...Hillmen, P. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *New England Journal of Medicine, 373*(3), 213–223. https://doi.org/10.1056/NEJMoai400376

Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A.,...O’Brien, S. (2013). Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *New England Journal of Medicine, 369*(1), 32–42. https://doi.org/10.1056/NEJMoai215637

Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S.,...Hallek, M. (2016). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. *Lancet Oncology, 17*(2), 200–211. https://doi.org/10.1016/s1470-2045(15)00465-9

Chaouli, D., Choquet, S., Sanhes, L., Mahe, B., Hacini, M., Fitoussi, O.,...Delmer, A. (2017). Relapsed chronic lymphocytic leukemia retreated with rituximab: Interim results of the PERLE study. *Leukemia & Lymphoma, 58*(6), 1366–1375. https://doi.org/10.1080/10428194.2016.1243673

Eichhorst, B., Fink, A. M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C.,...Hallek, M. (2016). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. *Lancet Oncology, 17*(7), 928–942. https://doi.org/10.1016/s1470-2045(16)30551-1

Eichhorst, B., & Hallek, M. (2016). Prognostication of chronic lymphocytic leukemia in the era of new agents. *Hematology American Society of Hematology Education Program, 2016*(1), 149–155. https://doi.org/10.1182/ashducation-2016.1.149

Farooqui, M. Z., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U.,...Wiestner, A. (2015). Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukemia with TP53 aberrations: A phase 2, single-arm trial. *Lancet Oncology, 16*(2), 169–176. https://doi.org/10.1016/s1470-2045(14)71182-9

Finnes, H. D., Chaffee, K. G., Call, T. G., Ding, W., Kenderian, S. S., Bowen, D. A.,...Parikh, S. A. (2016). Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. *Leukemia & Lymphoma, 1–8.*
of ibrutinib-treated patients in the United States: Large retrospective analysis of 621 real world patients [Abstract 3222]. Blood (ASH Annual Meeting Abstracts), 128.

Miller, M. D., Paradis, C. F., Houck, P. R., Mazumdar, S., Stack, J. A., Rifai, A. H.,...Reynolds, C. F., 3rd. (1992). Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Research, 41(3), 237–248. https://dx.doi.org/10.1016/0165-1781(92)90055-N

Montserrat, E., Bauman, T., & Delgado, J. (2016). Present and future of personalized medicine in CLL. Best Practice & Research Clinical Haematology, 29(1), 100–110. https://doi.org/10.1016/j.beha.2016.08.009

Novartis. (2017). Novartis pharmaceuticals. Retrieved from https://www.hcp.novartis.com/

O’Brien, S., Furman, R. R., Coutre, S. E., Shamar, J. P., Burger, J. A., Blum, K. A.,...Byrd, J. C. (2014). Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncology, 15(1), 48–58. https://doi.org/10.1016/s1470-2045(13)70513-8

Parikh, S. A., & Shanafelt, T. D. (2014). Risk factors for Richter syndrome in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 9(3), 294–299. https://doi.org/10.1007/s11899-014-0223-4

Parikh, S. A., & Shanafelt, T. D. (2016). Prognostic factors and risk stratification in chronic lymphocytic leukaemia. Seminars in Oncology, 43(2), 233–240. https://doi.org/10.1053/j.seminoncol.2016.02.009

Parikh, S. A., Strati, P. T., Tsang, M., West, C. P., & Shanafelt, T. D. (2016). Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood, 127(4), 1752–1760. https://doi.org/10.1182/blood-2015-10-620864

Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T.,...Hallek, M. (2014). Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 124(1), 49–62. https://doi.org/10.1182/blood-2014-02-556399

Pharmacyca. (2016). Imbruvica (ibrutinib) package insert. Retrieved from https://www.imbruvica.com/prescribing-information

Rai, K. R., & Jain, P. (2016). Chronic lymphocytic leukemia (CLL): Then and now. American Journal of Hematology, 91(3), 330–340. https://doi.org/10.1002/ajh.24282

Rai, K. R., Savitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., & Paterneck, B. S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219–234.

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F.,...Seymour, J. F. (2016). Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374(4), 311–322. https://doi.org/10.1056/NEJMoai151257

Roberts, A. W., & Huang, D. (2017). Targeting BCL2 with BH3 mimetics: Basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clinical Pharmacology & Therapeutics, 101(1), 89–98. https://doi.org/10.1002cpt.553

Roos-Weil, D., Nguyen-Khac, F., & Bernard, O. A. (2016). Chronic lymphocytic leukemia: Time to go past genomics? American Journal of Hematology, 91(5), 518–528. https://doi.org/10.1002/ajh.24301

Rossi, D, Gerber, B., & Stussi, G. (2017). Predictive and prognostic
biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia. *Leukemia & Lymphoma, 58*(7), 1548–1560. https://doi.org/10.1080/10428194.2016.1250264

Sarfati, D., Koczwara, B., & Jackson, C. (2016). The impact of comorbidity on cancer and its treatment. *CA: A Cancer Journal for Clinicians, 66*(4), 337–350. https://doi.org/10.3322/caac.21342

Schnekel, B., Hallworth, P., Rider, A., Macomson, B., & McRae, J., (2017). Comparing adherence levels of CLL treatment from both the patient and physician perspective in the U.S. [Abstract e19009]. *Blood (ASH Annual Meeting Abstracts), 35*(suppl).

Shanafelt, T. D., Parikh, S. A., Noseworthy, P. A., Goede, V., Chaffee, K. G., Bahlo, J.,...Kay, N. E. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). *Leukemia & Lymphoma, 58*(7), 1630–1639. https://doi.org/10.1080/10428194.2016.1257795

Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer statistics, 2017. *CA: A Cancer Journal for Clinicians, 67*(1), 7–30. https://doi.org/10.3322/caac.21387

Stauder, R., Eichhorst, B., Hamaker, M., Kaplanov, K., Morrison, V., Osterborg, A.,...Goede, V. (2016). Management of Chronic Lymphocytic Leukemia (CLL) in the Elderly: A Position Paper from an International Society of Geriatric Oncology (SIOG) Task Force. *Annals of Oncology, 28*(2), 218–227. https://doi.org/10.1093/annonc/mdw547

Thompson, P. A., Tam, C. S., O’Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W.,...Keating, M. J. (2016). Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. *Blood, 127*(3), 303–309. https://doi.org/10.1182/blood-2016-03-67675

Wierda, W. G. (2015). Updates to the management of chronic lymphocytic leukemia. *Journal of the National Comprehensive Cancer Network, 13*(5 suppl), 662–665. https://doi.org/10.6004/jnccn.2015.0197

Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B.,...Sundar, H. (2017). NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. *Journal of the National Comprehensive Cancer Network, 15*(3), 293–311. https://doi.org/10.6004/jnccn.2017.0030

Woyach, J. A., & Johnson, A. J. (2015). Targeted therapies in CLL: Mechanisms of resistance and strategies for management. *Blood, 126*(4), 471–477. https://doi.org/10.1182/blood-2015-03-585075

Yun, S., Vincelette, N. D., Acharya, U., & Abraham, I. (2017). Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: A systematic review and pooled analysis of four randomized controlled trials. *Clinical Lymphoma, Myeloma & Leukemia, 17*(1), 31–37. e13. https://doi.org/10.1016/j.clml.2016.09.010